111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib

Journal of Nuclear Medicine

Volumn 51, Issue 11, 2010, Pages 1707-1715

  Desar, Ingrid M E ^a   Stillebroer, Alexander B ^a   Oosterwijk, Egbert ^a   Leenders, William P J ^a   Van Herpen, Carla M L ^a   Van Der Graaf, Winette T A ^a   Boerman, Otto C ^a   Mulders, Peter F A ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

111In bevacizumab scintigraphy; Angiogenesis inhibitor; Biomarker; Renal cell carcinoma; Sorafenib

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BEVACIZUMAB IN 111; CARBONATE DEHYDRATASE IX; CD31 ANTIGEN; GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN; RADIOPHARMACEUTICAL AGENT; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN A; BENZENESULFONIC ACID DERIVATIVE; BEVACIZUMAB; DIAGNOSTIC AGENT; INDIUM; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SCINTISCANNING; CANCER SURGERY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY SCINTISCANNING; MALE; NEPHRECTOMY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TREATMENT DURATION; TUMOR VASCULARIZATION; ADJUVANT THERAPY; DRUG ANTAGONISM; KIDNEY TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; SCINTISCANNING; TIME;

ANTIBODIES, MONOCLONAL; BENZENESULFONATES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIUM RADIOISOTOPES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEPHRECTOMY; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79851500109     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.078030     Document Type: Article

References (31)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
2. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
3. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev. 2009;35:309-321.
4. Takahashi A, Sasaki H, Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994;54:4233-4237. (Pubitemid 24258135)
5. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res. 2002;62:2957-2961. (Pubitemid 34525785)
6. Raica M, Cimpean AM, Anghel A. Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma. Neoplasma. 2007;54:278-284.
7. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442. (Pubitemid 26102720)
8. Kusters B, de Waal RM, Wesseling P, et al. Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma. Cancer Res. 2003;63:5408-5413. (Pubitemid 37139858)
9. Roodink I, van der LJ, Kusters B, et al. Development of the tumor vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression. Int J Cancer. 2006;119:2054-2062. (Pubitemid 44423661)
10. Hoeben A, Landuyt B, Highley MS, Wildiers H, van Oosterom AT, de Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56:549-580. (Pubitemid 39658463)
11. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993;4:1317-1326. (Pubitemid 24045761)
12. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313-1319.
13. Stollman TH, Scheer MG, Leenders WP, et al. Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer. 2008;122:2310-2314. (Pubitemid 351542336)
14. Scheer MG, Stollman TH, Boerman OC, et al. Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: lack of correlation with VEGF-A expression. Eur J Cancer. 2008;44:1835-1840.
15. 177Lu, or 186Re. J Nucl Med. 2004;45:327-337.
16. 124I]iodinated- VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 2002;62:5912-5919.
17. 111In: an intrapatient comparison. Clin Cancer Res. 2003;9:3953S-3960S.
18. Scheer MGW, Stollman TH, Boerman OC, et al. Radiolabeled bevacizumab as a tracer of VEGF-expression in patients with colorectal liver metastasis. Eur J Cancer., in press.
19. Visser E, Postema E, Boerman O, Visschers J, Oyen W, Corstens F. Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND). Eur J Nucl Med Mol Imaging. 2007;34:413-421. (Pubitemid 46295350)
20. Span PN, Grebenchtchikov N, Geurts-Moespot J, Westphal JR, Lucassen AM, Sweep CG. EORTC Receptor and Biomarker Study Group Report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts. Int J Biol Markers. 2000;15:184-191. (Pubitemid 30389368)
21. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62. (Pubitemid 40093472)
22. Oosterwijk-Wakka JC, Kats-Ugurlu G, Leenders WP, et al. Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250. BJU Int. 2010.
23. Maity A, Bernhard EJ. Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy. Cancer Res. 2010;70:2141-2145.
24. Kapoor A, Gharajeh A, Sheikh A, Pinthus J. Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma. Curr Oncol. 2009;16 (suppl 1):S60-S66.
25. Steffens MG, Oosterwijk E, Zegwaart-Hagemeier NE, et al. Immunohistochemical analysis of intratumoral heterogeneity of [131I]cG250 antibody uptake in primary renal cell carcinomas. Br J Cancer. 1998;78:1208-1213. (Pubitemid 28479153)
26. Nicol D, Hii SI, Walsh M, et al. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol. 1997;157:1482-1486. (Pubitemid 27130856)
27. Tomisawa M, Tokunaga T, Oshika Y, et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer. 1999;35:133-137. (Pubitemid 29079504)
28. Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B. Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma. BJU Int. 2006;97:1102-1108.
29. Rivet J, Mourah S, Murata H, et al. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer. 2008;112:433-442.
30. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR. 2010;194:157-165.
31. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008;26:4572-4578.